Eli Lilly's bet on the Oscars shows the GLP-1 ad wars are heating up. - Eli Lilly. At the 2024 Academy Awards, Eli Lilly, the ...

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. | Once ...

Hims & Hers Health has blazed a red-hot streak, helped by the growing popularity of weight-loss drugs. But after a massive ...

First liraglutide generic cleared for diabetes Finally, the FDA has cleared the first generic of Novo Nordisk's once-daily injectable GLP-1 agonist Victoza (liraglutide), used to treat type 2 ...

Ahead of World Obesity Day, we examine the impact of the game-changing drugs that control appetite. Increasingly being taken ...

Novo Nordisk’s bid to provide a once-weekly basal insulin product for people with diabetes, reducing the number of injections needed, has hit a major hurdle in the US. The FDA sent the Danish ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...